Pharmaceuticals & Biologics

To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
FANC: Potentiating Melphalan in Multiple Myeloma by Targeting the Fanconi Anemia/BRCA Resistance Pathway 03B097
VEGF/PDGF: Orally Bioavailable Small Molecule that Binds VEGF or PDGF for the Treatment of Cancer or Age-Related Macular Degeneration 03B114
RhoB: Gene Therapy with RhoB Variants to Suppress Cancer Growth 04B102
STAT3: Using Platinum (IV) STAT3 Inhibitors to Enhance Immune Cell Antitumor Activity 04B112
MRP1: Small Molecule for Treating P-glycoprotein (Pgp)-Mediated Multi-Drug Resistance in Cancer 04MA001
Raf/Mek/P-Erk: Novel Use of Pirbuterol (ARA-211) for Cancer Therapy 05B072
Shp2: Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors 06A038
BCR-ABL: Vorinostat Co-treatment Enhances Dasatanib Efficacy in CML 06B078N
Rho Kinase: Inhibitors as Novel Anti-Cancer Agents 06B134
Glut-1: Method of Treating Cancer with Antibodies Against Glucose Transporter-1 07B083
SHIP: Selective SHIP-1 Phosphatase Inhibitor as a Novel Therapy for Tissue Graft Failure and Blood Cancers 08MB010
Topoisomerase II: Small Molecule Inhibitors of Nuclear Export of Topoisomerase II Alpha for Multiple Myeloma Treatment 08MB014
Rho Kinase (ROCK) Inhibitors as Anticancer Drugs 09MA015
Aurora: Novel Small Molecule Aurora A Kinase Inhibitor as a Cancer Therapeutic 09MA037
pH: Systemic Buffers as Inhibitors of Cancer Metastasis 09MB048
Mcl-1: Asymmetrical Marinopyrroles as Anti-Cancer Agents 10MA018N
LPAAT: Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer 10MA019N
FT/GGT: Novel Dual Inhibitor of Farnesyltransferase and Geranylgeranyltransferase-1 as an Anti-Cancer Agentbitor 10MB048
Proteasome: Non-covalent and Reversible Proteasome Inhibitors with an Oxadiazole-isopropylamide Core 10MB083
HDAC6: Novel Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group 12MA030
Mcl-1/Bcl-xL: Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents 12MA035N
IRE-1: Novel Small Molecule Inhibitors of IRE-1 for the Treatment of B-cell Cancer 12MB089
STAT3: Novel Small Molecule STAT3 Inhibitor for Cancer Treatment 12MB098
Novel Symmetrical Marinopyrrole Derivative as a Therapeutic against Resistant Bacterial Strains 12MB110
BRD4 JAK2: Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics 14MB069
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Non-Hodgkin’s Lymphoma (NHL) 14MB086N
WEE1: Small Molecule WEE1 Inhibitor (WEIN-159) that Inhibits WEE1 Phosphorylation of H2B but Not Cdc2 to Treat Can 14MB092
Ras: Small Molecules that Inhibit Mutant KRAS 15MA011
Ras/Raf: Stapled Peptides as Inhibitors of Mutant KRAS 15MA012
Aurora/JAK2: Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis 16MA005N
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL) 16MA023N
β-catenin/BCL-9: Small Molecules that Inhibit the β-catenin/BCL9 Interaction 17MA014
XBP-1: XBP-1 Inhibitor B-I09 for the Treatment of Acute GVHD and Solid Organ Rejection 17MB051
Ubiquitin Bispecific Antibody: Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor’s Degradation 17MB056N
β-catenin/TCF: Small Molecule Inhibitors of the Interaction of β-catenin and T-cell Factor 18MA018N
Novel BRD4/JAK2 Dual Inhibitor Cancer Therapeutics 18MB053
β-catenin/TCF: Small Molecule Peptidomimetic Inhibitors of the Interaction of β-catenin and T-cell Factor 18MB076